Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2022-06-30 00:00:00 ET · period of report 2022-06-29 · accession 0000886163-22-000103 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-06-30 | 2022-06-29 | LGND | Haas Jason | Dir | A - Grant | $0.00 | +1,750 | 1,750 | New | $0 |
| D | 2022-06-30 | 2022-06-29 | LGND | Haas Jason | Dir | A - Grant | $0.00 | +5,907 | 5,907 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-06-29 | A | A | 1,750 | $0.00 | 1,750 | D | — | — | |
| 2 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-06-29 | A | A | 5,907 | $0.00 | 5,907 | D | $88.48 · — to 2032-06-29 | 5,907 Common Stock | (F1) The option becomes exercisable in 3 successive annual installments upon completion of each calendar year of service beginning on the grant date. |